SEC Filing Summary: Renovaro Inc. (RENB)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Renovaro Inc. (not Lunai Bioworks Inc.) on August 6, 2025. The report addresses a compliance issue with The Nasdaq Stock Market LLC regarding the failure to hold an annual meeting of shareholders within the required timeframe.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status.
Material Changes and Events
- Delisting Notice: On July 7, 2025, the Company received notice from Nasdaq of non-compliance with Listing Rule 5620(a) for failing to hold an annual shareholder meeting within twelve months of the fiscal year-end.
- Compliance Plan Accepted: On August 5, 2025, Nasdaq accepted the Company's plan to regain compliance.
- Extension Granted: Nasdaq granted an extension until October 31, 2025, for the Company to hold its annual meeting.
Outlook, Risks, and Management Commentary
Management intends to hold the annual meeting within the granted extension period to regain full compliance with Nasdaq listing standards. The filing includes standard forward-looking statements cautioning that actual results may differ materially from plans due to risks and uncertainties beyond the Company's control.
Investor Verification Checklist
- Verify the exact date scheduled for the upcoming annual meeting of shareholders.
- Confirm the Company's current stock trading status on Nasdaq (RENB) to ensure no suspension has occurred.
- Review the Company's most recent 10-K or 10-Q for financial health, as this 8-K contains no financial data.
- Monitor for any further correspondence from Nasdaq regarding the October 31, 2025 deadline.